Literature DB >> 3562044

Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy.

J P Guggenbichler, F J Allerberger, M Dierich.   

Abstract

Excretion of an antibiotic bile may result in high intraintestinal concentrations and thus alteration in the fecal flora. We investigated the effect of ceftriaxone (45% biliary excretion) and cefotaxime (less than 5% biliary excretion) on the aerobic fecal flora. Ceftriaxone eradicated susceptible enteric organisms and resulted in overgrowth of Candida spp. and resistant enterococci. In some patients multiresistant gram negative bacteria appeared during of after therapy. Cefotaxime had a moderate effect on fecal microecology and did not promote the emergence of resistant organisms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3562044

Source DB:  PubMed          Journal:  Padiatr Padol        ISSN: 0030-9338


  4 in total

1.  Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.

Authors:  M J Dinubile; I Friedland; C Y Chan; M R Motyl; H Giezek; M Shivaprakash; R A Weinstein; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

2.  Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients.

Authors:  Yong-Tao Li; Cheng-Bo Yu; Jian-Rong Huang; Zheng-Ji Qin; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 4.  Risk factors and outcome of bacterial infections in cirrhosis.

Authors:  Tony Bruns; Henning W Zimmermann; Andreas Stallmach
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.